Extrait

Background and study aims We are conducting a feasibility study to see if offering people who inject heroin same day access to a GP and a methadone script (called opium substitution treatment (OST)) can help these individuals get into and stay on OST. We are focusing upon individuals who find it particularly hard to engage in OST or those who have recently dropped out of treatment. The reason why we are conducting this study is because we know that accessing OST reduces the risk of drug related deaths and blood borne virus transmission. Who can participate? Individuals (male and female) accessing the Bristol Drugs Project (BDP) needle exchange are asked if they are interested in participating in this study. Participants are eligible if they are injecting opiates (heroin), live in Bristol and are not currently receiving a script of OST. What does the study involve? Participants who consent and complete questionnaires at baseline are randomised into two groups either to receive the intervention i.e., receive a script of methadone on the same day, or, 'care as usual' (offer to make an appointment with GP to start OST). All participants are followed up at three months, complete further questionnaires and asked if they are still on a script of OST at this time point. What are the possible benefits and risks of participating? Participants may benefit from having same day access to a script of methadone rather than waiting up to one to two weeks (longer in some areas) for a script. Participants will need to spend about 30 minutes filling in questionnaires and be available to go to an appointment at the recruiting GP practice on the same day. They will also need to return at one and then two weeks later to renew their script. No other risks associated with this study. Where is the study run from? The study is run from the University of Bristol in collaboration with the Bristol Drugs Project (BDP), Bristol. When is the study starting and how long will it run for? The study started participant recruitment in October 2011. The aim was to recruit for one year or when the target sample (100) was achieved. This was completed in September 2012. Who is funding the study? This study is funded by funded by the NHS via the National Institute for Health Research (NIHR), Research for Patient Benefit (RfPB). Who is the main contact? Dr Angela Beattie [email protected]

Critère d'inclusion

• Drug misuse, individuals injecting opiates, opiate substitution treatment (OST)

Liens

• ictrp
• isrctn